Esperion Therapeutis.Inc. buy HC Wainwright
Summary
This prediction is currently active. With a performance of 129.51% the BUY prediction by HC_Wainwright is a big success. This prediction currently runs until 13.11.24. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | -12.694% | -12.694% |
iShares Core DAX® | -0.654% | 1.989% |
iShares Nasdaq 100 | 0.903% | 5.664% |
iShares Nikkei 225® | -0.740% | -1.363% |
iShares S&P 500 | -0.013% | 3.020% |
Comments by HC_Wainwright for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by HC_Wainwright for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
21.05.24
21.05.25
09:52
Esperion Therapeutis.Inc.
08.05.24
08.05.25
09:52
Esperion Therapeutis.Inc.
25.03.24
25.03.25
09:52
Esperion Therapeutis.Inc.
28.02.24
28.02.25
09:52
Esperion Therapeutis.Inc.
28.08.23
28.08.24
09:52
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24